Med­ic­aid com­mis­sion to Con­gress: In­crease re­bates for ac­cel­er­at­ed ap­proval drugs

As the FDA con­tin­ues to ap­prove more new drugs un­der its ac­cel­er­at­ed ap­proval path­way, the non-par­ti­san Med­ic­aid and CHIP Pay­ment and Ac­cess Com­mis­sion (MAC­PAC) is telling Con­gress to in­crease the statu­to­ry Med­ic­aid re­bates for such drugs un­til their clin­i­cal ben­e­fits have been ver­i­fied.

High­er re­bates for drugs with ac­cel­er­at­ed ap­provals, a move op­posed by the bio­phar­ma in­dus­try, would mean low­er net prices, less­en­ing their fi­nan­cial bur­den on the health care sys­tem while in­cen­tiviz­ing the com­pa­nies to speed the ver­i­fi­ca­tion of the drugs’ clin­i­cal ben­e­fits in con­fir­ma­to­ry tri­als. Once those ben­e­fits are con­firmed, the com­pa­nies would re­turn to the low­er re­bates when the ac­cel­er­at­ed ap­proval is con­vert­ed in­to a full ap­proval, MAC­PAC sug­gests.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.